Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.

Journal Article (Clinical Trial;Journal Article)

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.

Full Text

Duke Authors

Cited Authors

  • Moseley, RP; Davies, AG; Richardson, RB; Zalutsky, M; Carrell, S; Fabre, J; Slack, N; Bullimore, J; Pizer, B; Papanastassiou, V

Published Date

  • October 1990

Published In

Volume / Issue

  • 62 / 4

Start / End Page

  • 637 - 642

PubMed ID

  • 2223581

Pubmed Central ID

  • PMC1971477

International Standard Serial Number (ISSN)

  • 0007-0920

Digital Object Identifier (DOI)

  • 10.1038/bjc.1990.345


  • eng

Conference Location

  • England